- Home
- COP vs BMY Comparison
COP vs BMY Comparison
Compare COP & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COP
- BMY
- Stock Information
- Founded
- COP 1917
- BMY 1887
- Country
- COP United States
- BMY United States
- Employees
- COP N/A
- BMY N/A
- Industry
- COP Integrated oil Companies
- BMY Biotechnology: Pharmaceutical Preparations
- Sector
- COP Energy
- BMY Health Care
- Exchange
- COP Nasdaq
- BMY Nasdaq
- Market Cap
- COP 123.0B
- BMY 120.4B
- IPO Year
- COP N/A
- BMY N/A
- Fundamental
- Price
- COP $95.07
- BMY $57.28
- Analyst Decision
- COP Buy
- BMY Hold
- Analyst Count
- COP 17
- BMY 15
- Target Price
- COP $136.25
- BMY $55.93
- AVG Volume (30 Days)
- COP 9.1M
- BMY 11.6M
- Earning Date
- COP 02-06-2025
- BMY 02-06-2025
- Dividend Yield
- COP 3.28%
- BMY 4.33%
- EPS Growth
- COP N/A
- BMY N/A
- EPS
- COP 8.44
- BMY N/A
- Revenue
- COP $56,924,000,000.00
- BMY $47,435,000,000.00
- Revenue This Year
- COP N/A
- BMY $7.22
- Revenue Next Year
- COP $9.85
- BMY $0.16
- P/E Ratio
- COP $11.27
- BMY N/A
- Revenue Growth
- COP N/A
- BMY 5.56
- 52 Week Low
- COP $94.27
- BMY $39.35
- 52 Week High
- COP $135.18
- BMY $61.08
- Technical
- Relative Strength Index (RSI)
- COP 21.78
- BMY 50.79
- Support Level
- COP $102.40
- BMY $55.04
- Resistance Level
- COP $105.05
- BMY $58.55
- Average True Range (ATR)
- COP 2.09
- BMY 1.28
- MACD
- COP -0.91
- BMY -0.31
- Stochastic Oscillator
- COP 5.97
- BMY 44.36
About COP ConocoPhillips
ConocoPhillips is a US-based independent exploration and production firm. In 2023, it produced 1.2 million barrels per day of oil and natural gas liquids and 3.1 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2023 were 6.8 billion barrels of oil equivalent.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.